This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Illumina-Grail saga to resume imminently with EU gun-jumping penalty and unwinding measures

By Natalie McNelis ( January 5, 2023, 13:06 GMT | Insight) -- US life-sciences giant Illumina can expect its formal fining decision from the European Commission within weeks on charges of jumping the gun on its merger with cancer-detection specialist Grail, MLex has learned. The EU watchdog blocked the deal last September, and also expected soon is a decision on “restorative measures” that Illumina must take to unwind it.Illumina’s troubled bid to take over cancer-testing specialist Grail has provided merger watchers with a series of thrills and spills over the past two years, and more is to come in 2023....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login